Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells.
Rat intestinal epithelial cells (RIE-1) permanently transfected with the prostaglandin endoperoxide synthase 2 (also referred to as cyclooxygenase-2; COX-2) gene exhibit decreased cyclin D1 levels, decreased cdk4-associated kinase activity, and delayed G1 cell cycle progression, which represents a phenotype similar to that which follows transforming growth factor beta (TGF-beta) treatment. In the current study, we have found that addition of TGF-beta 1 to the parental RIE-1 cells (designated RIE-P) caused a rapid induction of COX-2 mRNA and protein. COX-2 protein levels progressively increased and reached peak levels 6 h after TGF-beta 1 addition. Cyclin D1 was decreased by 74% at 6 h and was undetectable 24 h after addition of TGF-beta 1. In RIE cells transfected with the COX-2 antisense expression vector (RIE-AS cells), TGF-beta 1 induction of COX-2 protein was reduced greater than 90%. Addition of TGF-beta 1 did not reduce the abundant cyclin D1 protein expression in the RIE-AS cells, unlike the effect in RIE-P cells. TGF-beta 1 treatment reduced peak [3H]thymidine incorporation by 60% and delayed G1/S-phase transition by at least 4 h in the RIE-P cells. In contrast, S-phase entry occurred at 16 h in RIE-AS cells and was not altered by TGF-beta 1 treatment. Restoration of cyclin D1 expression by transfection of the cyclin D1 cDNA under transcriptional control of the cytomegalovirus promoter/enhancer in the COX-2-overexpressing (RIE-S) cells decreased the time required for S-phase entry by at least 4 h and increased the peak level of [3H]thymidine incorporation. Taken together, the results demonstrate that TGF-beta 1 strongly induces COX-2 at both the mRNA and protein levels and suggest that this induction of COX-2 is involved in the down-regulation of cyclin D1 and inhibition of cell growth caused by TGF-beta 1 in rat intestinal epithelial cells.
Sheng
H
H
Department of Surgery, Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2279, USA.
Shao
J
J
Hooton
E B
EB
Tsujii
M
M
DuBois
R N
RN
Beauchamp
R D
RD
D000818:Animals; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins / Q000378:metabolism; D002455:Cell Division; D019938:Cyclin D1; D016213:Cyclins / Q000235:genetics / Q000378:metabolism; D051546:Cyclooxygenase 2; D004261:DNA Replication; D015536:Down-Regulation; D004790:Enzyme Induction; D007413:Intestinal Mucosa / Q000378:metabolism*; D007527:Isoenzymes / Q000096:biosynthesis* / Q000235:genetics; D015513:Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D010544:Peroxidases / Q000096:biosynthesis* / Q000235:genetics; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis* / Q000235:genetics; D051381:Rats; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000502:physiology*
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D016213:Cyclins; D007527:Isoenzymes; D015513:Oncogene Proteins; D016212:Transforming Growth Factor beta; D019938:Cyclin D1; D010544:Peroxidases; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases